Stock GBIM GLOBEIMMUNE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News GlobeImmune, Inc.

Equities

GBIM

US37957B1008

Market Closed - OTC Markets
Other stock markets
 02:43:20 2024-03-14 pm EDT 		5-day change 1st Jan Change
0.000001 USD -99.00% Intraday chart for GlobeImmune, Inc. -.--% -.--%
2022 Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital announced an offer to acquire 12.2% stake in GlobeImmune, Inc. for $7,000. CI
2017 NantCell, Inc. Exercises Option for Licensing Agreement with GlobeImmune, Inc. for GI-6100 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alternative Liquidity Index Announces Offer to Purchase Shares in GlobeImmune, Inc.
AQ
Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital announced an offer to acquire 12.2% stake in GlobeImmune, Inc. for $7,000.
CI
NantCell, Inc. Exercises Option for Licensing Agreement with GlobeImmune, Inc. for GI-6100
CI
NantCell, Inc. Enters into Licensing Agreement with GlobeImmune, Inc. for GI-4000
CI
NantCell, Inc. Enters into Licensing Agreement with GlobeImmune, Inc. for GI-6207 and GI-6301
CI
GlobeImmune, Inc. announced a financing transaction
CI
Gilead Sciences, Inc. Terminates the Collaboration and License Agreement with GlobeImmune
CI
GlobeImmune Inc. Announces Management and Board Changes
CI
GlobeImmune Inc.(OTCPK:GBIM) dropped from S&P TMI Index
CI
GlobeImmune Inc.(OTCPK:GBIM) dropped from NASDAQ Composite Index
CI
Globeimmune, Inc Announces Financial Results for the First Quarter Ended March 31, 2016
CI
GlobeImmune Seeks Alternatives
CI
GlobeImmune Inc.(NasdaqCM:GBIM) dropped from CRSP US Total Market Index
CI
GlobeImmune Inc. Reports Earnings Results for the Year Ended December 31, 2015; Provides Update on Clinical Programs
CI
GlobeImmune Inc. Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
CI
GlobeImmune Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2015
CI
GlobeImmune Weighing A Potential Sale
CI
GlobeImmune Explores Strategic Alternatives
CI
Globeimmune, Inc. Enters into License Agreement with Celgene Corporation
CI
Kirk Christoffersen to Leave GlobeImmune Inc. as Vice President, Corporate Development, Effective Aug. 3, 2015
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GBIM Stock
  4. News GlobeImmune, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW